↓ Skip to main content

Dove Medical Press

Article Metrics

Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy

Overview of attention for article published in International Journal of Women's Health, April 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
20 Mendeley
Title
Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy
Published in
International Journal of Women's Health, April 2012
DOI 10.2147/ijwh.s29346
Pubmed ID
Authors

Barry S. Komm, Mirkin

Abstract

Many women experience bothersome vasomotor and vaginal symptoms during the menopausal transition. Decreasing levels of estrogens during menopause are also associated with reduced bone density and an increased risk of osteoporosis. Combined estrogen/progestin therapy (hormone therapy) effectively treats menopausal symptoms and prevents bone loss, but has been associated with some safety and tolerability concerns. A novel menopausal therapy is the tissue selective estrogen complex, which pairs a selective estrogen receptor modulator with one or more estrogens. In preclinical studies, the tissue selective estrogen complex partnering bazedoxifene (BZA) with conjugated estrogens (CE) antagonized stimulation of breast and endometrial tissue, reduced vasomotor instability, and preserved bone mass in rat and mouse models. The specific attributes seen with BZA/CE were different from those observed with other selective estrogen receptor modulator/estrogen pairings. BZA/CE has undergone clinical evaluation in the Phase III Selective estrogens, Menopause, And Response to Therapy (SMART) trials in postmenopausal women with an intact uterus. Of the various doses of BZA/CE evaluated, BZA 20 mg/CE 0.45 mg and 0.625 mg were associated with a low incidence of endometrial hyperplasia (<1%) similar to placebo, and showed significant improvements in hot flushes and vulvar/vaginal symptoms and increases in bone mineral density. BZA 20 mg/CE 0.45 mg and 0.625 mg were associated with a low incidence of breast-related adverse events and demonstrated no difference from placebo in age-related changes in mammographic breast density. Both BZA/ CE doses showed a favorable tolerability profile, with no increases in uterine bleeding or breast tenderness, and had positive effects on metabolic parameters and quality of life. BZA/CE may be a promising alternative to hormone therapy for the treatment of menopausal symptoms and prevention of osteoporosis in nonhysterectomized postmenopausal women.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Iran, Islamic Republic of 1 5%
Unknown 19 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 20%
Student > Ph. D. Student 4 20%
Student > Master 3 15%
Student > Doctoral Student 2 10%
Other 2 10%
Other 2 10%
Unknown 3 15%
Readers by discipline Count As %
Medicine and Dentistry 7 35%
Nursing and Health Professions 3 15%
Psychology 2 10%
Agricultural and Biological Sciences 1 5%
Social Sciences 1 5%
Other 1 5%
Unknown 5 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2012.
All research outputs
#3,542,527
of 4,507,072 outputs
Outputs from International Journal of Women's Health
#212
of 273 outputs
Outputs of similar age
#58,723
of 75,177 outputs
Outputs of similar age from International Journal of Women's Health
#29
of 36 outputs
Altmetric has tracked 4,507,072 research outputs across all sources so far. This one is in the 3rd percentile – i.e., 3% of other outputs scored the same or lower than it.
So far Altmetric has tracked 273 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 75,177 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.